Surrogen’s Vice President of Research & Development, Dr. Adrienne Watson, PhD, is featured in GeneWorx Capital Webinar discussing the "Power of the Pig" in finding the next generation of Cancer Therapies.
EAGAN, Minn., Sept. 24, 2020 /PRNewswire/ -- Acceligen, a Recombinetics Inc. company, today announced that it received a grant from the Bill & Melinda Gates Foundation to develop bovine genetics optimized with traits desirable to smallholder dairy farmers. The breeding program will contribute to more sustainable production by using traits [...]
Eagan, MN, October 7, 2020–Recombinetics Inc., a leading gene editing company with platform technology in therapeutics development, today announced that it has merged its efforts with Makana Therapeutics, a leader in the field of xenotransplantation. Makana Therapeutics will become Recombinetics Inc.’s newest subsidiary and will be exclusively focused on solving [...]
Recombinetics, Inc. has recently been the focus of a series of media stories highlighting the discovery by the FDA of a plasmid insertion in one of the founding lines of its gene-edited, polled (hornless), cattle generated during a pilot study published in Nature Biotechnology (Carlson et al, 2016). The company did [...]
